NASDAQ:FLNA

Cassava Sciences Q3 2025 Earnings Results & Report

Cassava Sciences logo
$0.53 +0.05 (+11.15%)
As of 02:47 PM Eastern

Cassava Sciences beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.22 versus the -$0.27 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
8:00 AM ET

Cassava Sciences EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cassava Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cassava Sciences Q3 2025 Earnings FAQ

Cassava Sciences (NASDAQ:FLNA) reported earnings of -$0.22 per share for Q3 2025, beating the consensus estimate of -$0.27. The report was announced on Wednesday, November 12, 2025.

Cassava Sciences Earnings Headlines

Cassava Sciences (NASDAQ:FLNA) Stock Sees Heavy Call Option Buying
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Cassava Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cassava Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cassava Sciences and other key companies, straight to your email.

About Cassava Sciences

Cassava Sciences (NASDAQ:FLNA) is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences.

Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests.

Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018. It is headquartered in Austin, Texas, and has been led by founder and chief executive Remi Barbier.

View Cassava Sciences Profile